Please assess the completion status of the following clinical trial:

Trial Title: HL-085 in NRAS-mutated Advanced Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 Years or older (male or female).~* Patients have histologically or cytologically confirmed Unresectable stage III or IV melanoma;~* Able to provide the genetic test report with documented NRAS mutation at baseline.~* At least one target lesion as per RECIST v1.1 criteria.~* Previous chemotherapy, immunotherapy, or radiotherapy must have been completed at least 4 weeks prior to study drug administration, and all related toxic reactions (with the exception of alopecia) must have been resolved (to Grade ≤1 or baseline) prior to study drug administration.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.~* Life expectancy \> 3 months.~* No major surgery (excluding baseline tumor biopsy) or major trauma occurred at least 14 days prior to study drug administration.~Exclusion Criteria:~* Patients with active central nervous system (CNS) lesions (i.e., radiological evidence of instability, symptomatic lesions) should be excluded. Note: Patients receiving stereotactic brain radiotherapy or surgery who have shown no brain disease progression over a period of 3 months or longer are eligible for inclusion.~* Patients had received any other study treatment within the past 4 weeks prior to study drug administration.~* Inability to swallow the capsule, refractory nausea and vomiting, malabsorption, extracorporeal biliary shunt, or any small intestinal resection that would preclude adequate absorption of the study drug.~* ECG QTcB ≥ 480 msec (adjusted by Bazetts formula) during screening, or a history of congenital long QT syndrome.~* Bleeding symptoms of Grade 3 as defined by the National Cancer Institute General Terminology Standard for Adverse Events (NCI CTCAE V5.0) within the past 4 weeks prior to study initiation.~* One of the following situations occurs within the past 6 months prior to administration of study drug: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass grafting, symptomatic congestive heart failure, serious arrhythmia, uncontrolled hypertension, cerebrovascular accident, or transient ischemic attack, or symptomatic pulmonary embolism.~* Current use of other anti-cancer drugs (hormone therapy was acceptable).~* Uncontrolled concomitant diseases or infectious diseases.~* Patients have retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED) or other retinal diseases previously or currently.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HL-085 (Type: EXPERIMENTAL): 12 mg BID HL-085

Based on this trial design, predict the completion outcome and termination type (if applicable).